



A Newsletter on
CLINICAL PHARMA PRACTICE
An Update on Clinical Research and Drug Information



Volume : 9


Issue : 3

September - December - 2023

An Official Publication from
Department of Pharmacy Practice,
Swamy Vivekanandha College of Pharmacy,
Tiruchengode, Namakkal (Dt), Tamilnadu.
E-mail : svcpdpic@gmail.com

Patron : Prof. Dr. M. KARUNANITHI, B.Pharm., M.S., Ph.D., D.Litt.,
Advisory Board : Dr. S. ARTHANAREESWARAN, M.D., (General Medicine)
Dr. K. SREERAAGHANIDHI ARTHANAREESWARAN, M.S., (Ophthal)
Dr. G. MURUGANANTHAN, (Principal - SVCP)
Chief Editor : Dr. P. SHARMILA NIROJINI, (Professor & HoD)
Editorial Board : Mr. A. PRATHAP, (Asst. Prof. - Pharmacy Practice)
Dr. V. SHANGAVI, (Asst. Prof. - Pharmacy Practice)
Dr. P. DHIVYAPRASATH, (Asst. Prof. - Pharmacy Practice)
Dr. REDLIN JANI. R. R, (Asst. Prof. - Pharmacy Practice)
Dr. MILAGRIN XAVIER, (Asst. Prof. - Pharmacy Practice)

PHARMACIST DESK - TOMATO FLU



The global alarm surrounding the emergence of the "tomato flu" in India has escalated, with its first identification in Kerala on 6th May 2022. The viral infection has impacted over 100 children under 5 years old across various states, including Haryana, Odisha, Tamil Nadu, and Kerala, by 26th August 2022.

Initially believed to be linked to Hand, Foot, and Mouth Disease (HFMD), the tomato flu is now attributed to Coxsackie virus A-6 and A-16, both members of the Enterovirus group. It presents with distinctive red, tomato-like painful blisters, reminiscent of those observed in patients with monkey pox. The disease primarily affects children aged 1 to 10 and immuno compromised adults, potentially due to close contact with infected individuals and contaminated surfaces.

Symptoms include mild fever, joint swelling, fatigue, nausea, diarrhea, sore throat, poor appetite, and rashes. Diagnostic testing involves serological and molecular tests to distinguish it from similar viral infections such as COVID-19 and chikungunya. Unfortunately, no definitive treatment or vaccines are currently available for the tomato flu.

In terms of management, patients are isolated for 5-7 days, ensuring adequate fluid intake, rest, and symptomatic treatment. While most cases resolve without severe complications, there have been rare instances of muscle paralysis and encephalitis.

Research indicates that efforts to control the tomato flu outbreak involve heightened health surveillance, prompt testing, and interventions by Indian health authorities, drawing from the lessons learned during the COVID-19 pandemic. Preventive measures center around isolating cases, rigorous health monitoring, and collaborative global initiatives involving local and international health agencies. Emphasizing sanitation, providing parental guidance, continuous monitoring, and researching treatments and vaccinations are critical steps. A unified approach to disease surveillance, testing, and global cooperation is essential for containing this highly contagious tomato flu.

Dr. P. DHIVYAPRASATH, Pharm.D, PgDRA,
Asst. Professor, Dept. of Pharmacy Practice

DRUG MONOGRAPH

GEPIRONE

CATEGORY : ANTIDEPRESSANTS

INDICATION :

Major depressive disorder

MECHANISM OF ACTION :

The mechanism of gepirone is not fully understood but it is related to modulation of serotonergic activity in the CNS through selective agonist activity at 5HT1A receptors.

DOSAGE :

★ ADULT DOSING :

Initial, 18.2 mg orally once daily at about same time each day

CONTRAINDICATION :

- ★ Known hypersensitivity
- ★ Prolonged QTc interval
- ★ Congenital long QT syndrome.
- ★ Concomitant use of strong CYP3A4 inhibitors.
- ★ Severe hepatic impairment.
- ★ Concomitant use of MAOIs, including line zolid or IV methylene blue.

WARNING AND PRECAUTION :

★ Psychiatric : Suicidal thoughts and behaviors have been reported with SSRIs and other antidepressants in adolescents (unapproved use) and young adults.

★ Serotonin syndrome : Life - threatening serotonin syndrome may occur with concomitant use with SSRIs or tricyclic antidepressants.

ADVERSE EFFECTS :

Gastrointestinal : Abdominal pain (7%), Diarrhea (10%), Increased appetite (5%), Indigestion (6%), Nausea (35%), Vomiting (7%), Xerostomia (8%)

Neurologic : Dizziness (49%), Headache (31%), Insomnia (14%), Somnolence, Tired

Respiratory : Upper respiratory infection (8%)

MEDICATION COUNSELLING :

- ★ Inform patient to immediately report symptoms of QT prolongation.
- ★ Counsel patient to report symptoms of serotonin syndrome.
- ★ Instruct patient to report worsening suicidal ideation, unusual changes in behaviour, and symptoms of mania or hypomania.
- ★ Recommend patient to take at the approximately the same time every day with food.
- ★ Counsel patient to avoid concomitant use of Perforate St. John's Wort plant.

DRUG APPROVED ON : 22nd SEPTEMBER 2023

REFERENCE : www.micromedxsolution.com

ANGELIN GRACE T, V-PHARM.D

ANN JENCY A, V-PHARM.D

PHARMACY NEWS

IXCHIQ VACCINE FOR CHIKV



Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), an RNA virus in the alphavirus genus of the family Togaviridae. Chikungunya virus is transmitted by mosquitoes, most commonly *Aedes (Stegomyia) aegypti* and *Aedes (Stegomyia) albopictus*, which can also transmit dengue and Zika viruses.

These mosquitoes bite primarily during daylight hours. IxchIQ is a first chikungunya virus vaccine used to prevent chikungunya disease. IxchIQ contains a live, weakened version of the chikungunya virus that helps build up an immune response to the chikungunya virus to prevent potentially debilitating chikungunya disease used for people 18 and older who have an increased risk of being exposed to chikungunya virus. IxchIQ should not be used if you have a weakened immune system due to medications used for hematologic and solid tumors, are on chemotherapy, have a history of congenital immunodeficiency, long-term immunosuppressive therapy, or patients with HIV infection who are severely immune compromised. IxchIQ is given as a single injection into the muscle (intramuscular injection).

Collected by :

EZHIL DEVI M, GAYATHRI R, V-PHARM.D

DRUG SAFETY ALERTS IDENTIFIED AND ISSUED BY PvPi

ISSUING DATE	SUSPECTED DRUGS	INDICATION(S)	ADVERSE DRUG REACTION
27 th Sep 2023	Esomeprazole	GERD, erosive reflux esophagitis, prevention of relapse of esophagitis & helps in eradication of H. Pylori associated peptic ulcer, Zollinger - Ellison syndrome.	Hyperprolactinaemia
25 th Oct 2023	Co-trimoxazole	Respiratory tract infection, urogenital infections, G.I. tract infections.	Fixed Drug Eruption
30 th Nov 2023	Mefenamic Acid	Rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever, dental pain	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome

SWAMY VIVEKANANDHA COLLEGE OF PHARMACY - ADR MONITORING CENTRE

DEPARTMENT ACTIVITIES

3rd NATIONAL PHARMACOVIGILANCE WEEK - 2023 CELEBRATION

Theme : Boosting Public Confidence in Pharmacovigilance

DATE : 15th SEPTEMBER 2023

EVENT : School children sensitization program

VENUE : Vivekanadha Vidhya Bhavan Matric Hr. Sec. school. Tiruchengode.

DATE : 16th SEPTEMBER 2023

EVENT : ADR Awareness pamphlet distribution by Pharm. D interns at VMCH.

DATE : 17th SEPTEMBER 2023

EVENT : Video making and slogan competitions at SVCP.

DATE : 19th SEPTEMBER 2023

EVENT : School children sensitization programme.

VENUE : SKV Matric Higher Secondary School, M. Kadampalayam. Tiruchengode.

DATE : 20th SEPTEMBER 2023

EVENT : Virtual ADR case presentation competition. Winners awarded with cash prizes.

DATE : 22nd SEPTEMBER 2023

Topic : Industry Practices and Career Opportunities

Speaker: Dr. Vijay Venkatraman, MBBS, Managing Director & CEO, Oviya Medsafe, Coimbatore.



STUDENT PARTICIPATION

Ms. Gayathiri V- Pharm.D, Ms. Preethika IV-Pharm.D, Ms. Gayathiri IV-Pharm.D, Ms. Janai B.SIV- Pharm.D, Ms. Mounsiha IV – Pharm.D attended the user Group Meeting – Elevating Clinical Decision Making with Evidence Based Drug and Disease information at Coimbatore on 27th November 2023.



STUDENT ACHIEVEMENT

Ms. J. Christy Immaculate & Ms. Kanishgasree of III -Pharm.D participated in slogan writing and video making competition and won 3rd & 1st prizes respectively organized by SVCP-VMCH-AMC on the event of National Pharmacovigilance week during 17th to 23rd September 2023



ISPOR ACTIVITIES

The ISPOR - SVCP Student Chapter organized a quiz completion. 20th December 2023 Our SVCP students participated in multiple rounds, Winners awarded with cash prizes, of ₹5000, ₹3000 and ₹2000.

OUTREACH ACTIVITIES

WORLD PHARMACIST DAY

V - Pharm.D students commemorated the world pharmacist day on 25th September 2023 at SVCP.

WORLD POLLUTION PREVENTION DAY

IV - Pharm. D students and ISPOR SVCP student chapter commemorated World Pollution Prevent day on 19th December 2023 at Government Middle School, Sathinayakkampalayam.



NATIONAL PHARMACIST DAY

All faculty members actively participated in Oath taking done at SVCP ground during National Pharmacist Day celebration organized by V - Pharm. D on 25th September 2023.



PUBLICATIONS

- ★ **Palanisamy SN**, Rajan RJ, Reddy MMK, Udayakumaran N, Karthik NS, et al. (2023) Unraveling the Anticancer Properties of Mannose: A Comprehensive Review and Prospects for Clinical Translation. J Pharm Drug Res, 6(3): 766-770.
- ★ **Nirojini PS**, Bhuvaneshwari NK, Dharsshini N, Bharathi SD, Velavan K. Therapeutic Drug Monitoring of 5-Fluorouracil in Head and Neck Cancer Patients: An Interventional Pilot Study. Ind J Med Paediatr Oncol.2023; DOI <https://doi.org/10.1055/s-0043-1776294>.
- ★ **Nithyakala P**, Jessly Lalu, Karthiga.R, Karthika. J. An Overview of Surgical Site Infection and its Risk Factors, Pathogens, Treatment and Prevention. International Journal of Innovative Science and Research Technology. 2023;8 (9):1488-1497.
- ★ **Nithya R**, Swetha D, Lavanya S, Madhumitha V. Adult onset still disease-An overview. International Journal of All Research Education and Scientific Methods. 2023;11(10); 1716-1725.
- ★ Kumar SS, **Shangavi V**, Reema MS, Saju SM, Varghese S, Kunjumon SA, Swetha D. A Case Report on Contrast Media Induced Acute Kidney Injury after Percutaneous Coronary Intervention. Indian Journal of Pharmacy Practice. 2023;16(4): 369- 372.
- ★ **Prathap A**, Divya RP, Femina H, Gayathri P, Jensilin Devakumari T, Jessly Lalu. Septic Arthritis – An overview. International Journal of Innovative Research In Technology(IJIRIT).2023;10(4): 474-478.
- ★ **P. Dhivyaprasath**, Abi Monika A P, Aarthi A, S. Abirami, Aditya J. A role of prophylactic antibiotics in preventing surgical site infection: current practice and future direction. Int J Health Sci Res. 2023;13(12):293-299. DOI: 10.52403/ijhsr:20231235



Book Post

Please send your suggestions to The Chief Editor

CLINICAL PHARMA PRACTICE NEWSLETTER

Drug & Poison Information Centre,

Department of Pharmacy Practice,

Swamy Vivekanandha College of Pharmacy

Tiruchengode, Namakkal (Dt)., Tamilnadu.

To